You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Optimizing Combination Endocrine Therapy in Advanced HR-Positive Breast Cancer

  • Authors: Nadia Harbeck, MD, PhD; Javier Cortés, MD, PhD; Thomas Bachelot, MD
  • CPD Released: 1/31/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 1/31/2018
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists, obstetricians/gynecologists, and pathologists involved in the treatment of patients with hormone receptor (HR)-positive advanced breast cancer.

The goal of this activity is to improve physicians' understanding regarding the use of cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy for treating HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients.

Upon completion of this activity, participants will:

  1. Have greater competence regarding proper treatment approaches for postmenopausal HR-positive, HER2-negative metastatic breast cancer patients
  2. Have greater competence related to managing adverse effects associated with the use of CDK4/6 inhibitors in combination with endocrine therapy
  3. Have greater knowledge related to applying clinical trial data to clinical practice for the use of CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer patients


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Moderators

  • Nadia Harbeck, MD, PhD

    Professor, Breast Center, Department of Obstetrics and Gynecology, University of Munich, Munich, Germany

    Disclosures

    Disclosure: Nadia Harbeck, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc
    Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation; Pfizer Inc

  • Javier Cortés, MD, PhD

    Head, Breast Cancer and Gynecological Tumours, Ramón y Cajal University Hospital, Oncology Department, Madrid, Spain; Clinical Investigator, Breast Cancer Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain

    Disclosures

    Disclosure: Javier Cortés, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biothera Pharmaceuticals, Inc.; Celgene Corporation; Cellestia Biotech; Roche
    Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche

  • Thomas Bachelot, MD

    Head, Medical Oncology Department, Centre Léon Bérard, Lyon, France

    Disclosures

    Disclosure: Thomas Bachelot, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceutical Corporation; Pfizer Inc.; Roche
    Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation Reviewed grants for clinical research from: Novartis Pharmaceutical Corporation; Roche

Steering Committee

  • Nadia Harbeck, MD, PhD

    Disclosures

    Disclosure: As listed above

  • Javier Cortés, MD, PhD

    Disclosures

    Disclosure: As listed above

  • Angelo Di Leo, MD, PhD

    Head, Medical Oncology Unit; Chair, Oncology Department, "Sandro Pitigliani" Medical Oncology Unit - Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

    Disclosures

    Disclosure: Angelo Di Leo, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare Corporation; Celgene Corporation; Eisai Co., Ltd; Genomic Health; Ipsen; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc; Pierre Fabre; Roche

  • Stephen R.D. Johnston, MA, FRCP, PhD

    Professor of Breast Cancer Medicine, Royal Marsden Hospital, London, United Kingdom

    Disclosures

    Disclosure: Stephen R.D. Johnston, MA, FRCP, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc; Puma Biotechnology; Roche
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Pfizer Inc; Puma Biotechnology
    Received grants for clinical research from: GlaxoSmithKline; Pfizer Inc

  • Xavier Pivot, MD, PhD

    Professor, J Minjoz University Hospital, Besançon, France

    Disclosures

    Disclosure: Xavier Pivot, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Roche
    Served as a speaker or a member of a speaker's bureau for: Eisai Co., Ltd; Novartis Pharmaceuticals Corporation; Roche

  • Sunil Verma, MD, MSEd, FRCPC

    Professor, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

    Disclosures

    Disclosure: Sunil Verma, MD, MSEd, FRCPC, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche

Editor

  • Deborah Middleton, MS

    Scientific Director, WebMD Global, LLC

    Disclosures

    Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Content Reviewer

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Optimizing Combination Endocrine Therapy in Advanced HR-Positive Breast Cancer

Authors: Nadia Harbeck, MD, PhD; Javier Cortés, MD, PhD; Thomas Bachelot, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 1/31/2017

Valid for credit through: 1/31/2018

processing....